DermWire | Newest Articles http://practicaldermatology.com/dermwire/ Newest Articles en-us Sun, 28 May 2017 18:34:12 GMT Sun, 28 May 2017 18:34:12 GMT DermWire May 26, 2017 is Don’t Fry Day http://practicaldermatology.com/dermwire/view.asp?url=may-26-2017-is-dont-fry-day The Friday before Memorial Day (May 26, 2017) is Don’t Fry Day. The day, designated by the American Society for Dermatologic Surgery Association (ASDSA) in collaboration with the National Council on Skin Cancer Prevention (NCSCP), serves as part of a public awareness campaign that aims to reduce the incidence of skin cancer by promoting sun safety and encouraging the public to protect their skin while enjoying the outdoors. While participating in Don’t Fry Day last year, ASDSA … Thu, 25 May 2017 04:00:00 GMT Sensus Healthcare Wins Technology Award from Greater Miami Chamber of Commerce http://practicaldermatology.com/dermwire/view.asp?url=sensus-healthcare-wins-technology-award-from-greater-miami-chamber-of-commerce Sensus Healthcare, Inc. was awarded the 2017 Technology Leader of the Year for the Disruptive Technology by The Greater Miami Chamber of Commerce. Sensus provides a non-invasive, cost-effective treatment for NMSC and keloids using the company’s proprietary, FDA-cleared, low-energy X-ray radiation technology known as SRT, which has effectively and safely treated oncological and non-oncological skin conditions in thousands of patients to date. “At Sensus, we are committed to providi… Wed, 24 May 2017 04:00:00 GMT Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumab http://practicaldermatology.com/dermwire/view.asp?url=sun-pharma-announces-us-fda-filing-acceptance-of-biologics-license-application-for-tildrakizumab The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The BLA filing for tildrakizumab was submitted by Merck & Co., Inc., Kenilworth, NJ, USA. Sun Pharmaceutical Industries Ltd.'s wholly owned subsidiary acquired worldwide rights to tildrakizumab from Merck (through a Merck subsidiary), known a… Wed, 24 May 2017 04:00:00 GMT Largest Psoriasis Meta-Analysis to Date Yields New Genetic Clues http://practicaldermatology.com/dermwire/view.asp?url=largest-psoriasis-meta-analysis-to-date-yields-new-genetic-clues A new meta -analysis identifies 16 additional genetic markers that may help researchers get closer to understanding how -- and why -- psoriasis develops. University of Michigan researchers, working with partners across the globe, published the work in Nature Communications. “We know there are a lot of genes, each with a relatively small effect, in play. Those genes combined with the environment lead people to develop psoriasis,” says senior author James T. Elder, M.D., Ph.… Wed, 24 May 2017 04:00:00 GMT Kristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch RHOFADE http://practicaldermatology.com/dermwire/view.asp?url=kristin-chenoweth-kicks-off-less-red-more-you-campaign-to-launch-rhofade Emmy and Tony award-winning actress and singer Kristin Chenoweth is kicking off Allergan’s Rhofade "Less Red, More You" campaign. Chenoweth, who has rosacea, will begin a nationwide conversation about the condition while raising awareness for RHOFADE (oxymetazoline HCl) cream, 1%, a new product indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. “As a performer who is constantly on stage or in front of the camera, it&#… Wed, 24 May 2017 04:00:00 GMT Tweaking TWEAK May Cool Inflammation in Pso and AD http://practicaldermatology.com/dermwire/view.asp?url=research-breakthrough-tweak-implicated-in-psoriasis-ad New research pinpoints a common driver of skin inflammation in both psoriasis and atopic dermatitis. The findings, published in the May 22, 2017 issue of Nature Communications, showed that TWEAK, a protein related to tumor necrosis factor (TNF), plays a major role in inducing pro-inflammatory signaling molecules that recruit immune cells to the skin. "Atopic dermatitis and psoriasis are two distinct diseases that are induced by alternate immune responses and the factors involved are q… Tue, 23 May 2017 04:00:00 GMT Statement from AAD President Henry W. Lim, MD, FAAD, on the Safety of Sunscreen http://practicaldermatology.com/dermwire/view.asp?url=statement-from-aad-president-henry-w-lim-md-faad-on-the-safety-of-sunscreen “The American Academy of Dermatology wants to emphasize that sunscreen remains a safe, effective form of sun protection. As one component of a daily sun-protection strategy, sunscreen is an important tool in the fight against skin cancer, including melanoma, the deadliest form of skin cancer. Current scientific data does not support claims that sunscreen ingredients are toxic or a hazard to human health. Rather, evidence supports the benefits of applying sunscreen to minimize short- and… Mon, 22 May 2017 04:00:00 GMT Consumer Reports: One-Third of Tested Sunscreens Delivered Less Than Half of Labeled SPF Protection http://practicaldermatology.com/dermwire/view.asp?url=consumer-reports-one-third-of-tested-sunscreens-delivered-less-than-half-of-labeled-spf-protection For the fifth year in a row, Consumer Reports’ testing has shown that some sunscreens failed to provide the level of protection promised on the package. Of the more than 60 lotions, sprays, sticks, and lip balms in our ratings this year, 23 tested at less than half their labeled SPF number. To check for UVB (SPF) protection, a standard amount of each sunscreen is applied to small areas of our panelists’ backs. Then they soak in a tub of water. Afterward, each area is exposed to si… Thu, 18 May 2017 04:00:00 GMT SkinCeuticals Study Finds Antioxidants Protect Against Atmospheric Skin Aging http://practicaldermatology.com/dermwire/view.asp?url=skinceuticals-study-finds-antioxidants-protect-against-atmospheric-skin-aging Exposure to ozone pollution zaps our collagen supply, according to new research from SkinCeuticals in partnership with Professor Giuseppe Valacchi from the University of Ferrara, Italy. After exposure to 0.8ppm ozone, collagen was reduced on live skin, the study showed. In addition, ozone pollution oxidizes lipids and depletes skin's natural antioxidant reservoir, triggering a progressive cascade of damage that may contribute to signs of skin aging. The findings are slated to be publis… Wed, 17 May 2017 04:00:00 GMT Valeant Dermatology Announces New Senior Leadership Team in Advance of SILIQ Launch http://practicaldermatology.com/dermwire/view.asp?url=valeant-dermatology-announces-new-senior-leadership-team-in-advance-of-siliq-launch Valeant Dermatology announced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman. The team includes Michael McMyne, vice president of sales; Stacey Williams, vice president of marketing; Charles Hahn, vice president of professional and specialty development; Ed Shupenus, executive director of marketing operations; and Steve Kreider, executive director of sales and marketing for SILIQ™ (brodalumab) injection, for subcutaneous use. In thei… Wed, 17 May 2017 04:00:00 GMT CVS Pharmacy's New Long Live Skin Campaign Aims to Increase Awareness of Skin Health http://practicaldermatology.com/dermwire/view.asp?url=cvs-pharmacys-new-long-live-skin-campaign-aims-to-increase-awareness-of-skin-health CVS Pharmacy, the retail division of CVS Health, is rolling out a new multi-platform Long Live Skin campaign to increase awareness about skin health, sun safety and proper skincare. The Long Live Skin Campaign kicks off today online and across CVS Pharmacy social handles with a video where women share "advice to their younger self." The women offered their guidance on a variety of life topics including love, loss, courage, and embracing both inner and outer beauty. The campaign wa… Mon, 15 May 2017 04:00:00 GMT BERG and debra of America Partner to Raise Awareness of EB http://practicaldermatology.com/dermwire/view.asp?url=berg-and-debra-of-america-partner-to-raise-awareness-of-eb Biopharmaceutical company BERG and the non-profit patient advocacy group Dystrophic Epidermolysis Bullosa Research Association of America (debra of America) are partnering up to help patients and families affected by epidermolysis bullosa (EB). EB is a rare, pervasive, and debilitating connective tissue disorder with many genetic and symptomatic variations that affects approximately one in every 20,000 children born in the U.S. The condition significantly diminishes the quality of life for th… Mon, 15 May 2017 04:00:00 GMT The American Society for Laser Medicine and Surgery Names New Officers http://practicaldermatology.com/dermwire/view.asp?url=the-american-society-for-laser-medicine-and-surgery-names-new-officers The American Society for Laser Medicine and Surgery (ASLMS) introduced Mathew M. Avram, MD, JD, as its new President at the Annual Conference in April. Dr. Avram succeeds Kristen M. Kelly, MD, who now serves as the Society’s Past President. The 2017-18 ASLMS Executive Committee also includes Dieter Manstein, MD, PhD, elected as Vice President, President-Elect Eric F. Bernstein, MD, MSE, Secretary Suzanne L. Kilmer, MD, Treasurer E. Victor Ross, MD and Historian J. Stuart Nelson, MD, PhD. … Mon, 15 May 2017 04:00:00 GMT Study: Smiling May Not Make Us Appear Younger After All http://practicaldermatology.com/dermwire/view.asp?url=study-smiling-may-not-make-us-appear-younger-after-all Conventional wisdom suggests that smiling makes you appear younger, but researchers at Ben-Gurion University of the Negev in Israel beg to differ. People who smile are actually perceived as older than those with a deadpan or surprised expression, according to a study published in the May 8th issue of Psychonomic Bulletin and Review. “Popular media promotes the idea that smiling makes you look younger,” adds Professor Tzvi Ganel, head of the Laboratory for Visual Perception and… Thu, 11 May 2017 04:00:00 GMT RCM Imaging of Skin Granted Reimbursement Codes by CMS; Wider Adoption Likely http://practicaldermatology.com/dermwire/view.asp?url=rcm-imaging-of-skin-granted-reimbursement-codes-by-cms After more than two decades of effort, reflectance confocal microscopy (RCM) imaging of skin has been granted reimbursement codes by the US Centers for Medicare and Medicaid Services. A report in Lasers in Surgery and Medicine highlights this 20-year journey, with an eye toward the next 20 years. RCM imaging of skin is a successful non-invasive tool in identifying benign lesions that can spare patients a skin biopsy. The RCM imaging procedure now has a granted category I current procedura… Tue, 9 May 2017 04:00:00 GMT FDA Accepts Aclaris Therapeutics’ NDA for Topical Treatment of Seborrheic Keratosis http://practicaldermatology.com/dermwire/view.asp?url=fda-accepts-aclaris-therapeutics-nda-for-topical-treatment-of-seborrheic-keratosis The FDA has accepted Aclaris Therapeutics' New Drug Application (NDA) for A-101 40% topical solution, an investigational drug for the potential treatment of seborrheic keratosis (SK). The NDA acceptance by the FDA in its 74-day letter indicates that the application is sufficiently complete to permit a substantive review. The PDUFA target action date for the completion of the FDA’s review of the NDA is December 24, 2017. If approved, A-101 40% would be the first FDA-approved topical med… Tue, 9 May 2017 04:00:00 GMT Unilever Ventures Invests in Nutrafol http://practicaldermatology.com/dermwire/view.asp?url=unilever-ventures-invests-in-nutrafol Unilever Ventures, the venture-capital and private-equity arm of consumer packaged goods conglomerate, has emerged as lead investor at the conclusion of series A financing round for Nutrafol®. Investment platform CircleUp made an initial introduction to the brand. With continued investment in research and clinical studies, Nutrafol says it is poised to take the lead in the fragmented multibillion dollar global hair loss industry. “Up until now, physicians have had very few, if any, … Tue, 9 May 2017 04:00:00 GMT DerMend’s New Line Takes On Mature Skin Issues http://practicaldermatology.com/dermwire/view.asp?url=dermends-new-line-takes-on-mature-skin-issues DerMend® is launching DerMend® Mature Skin Solutions. The new product line features DerMend®Fragile Skin Moisturizing Formula, DerMend® Moisturizing Anti-Itch Lotion and DerMend® Moisturizing Bruise Formula. It targets individuals with mature skin in their 50’s, 60’s, and 70’s and beyond. Mature skin may become thinner as collagen levels drop, the skin may become more fragile, bruise more easily and may become chronically itchy. DerMend® Fragile S… Tue, 9 May 2017 04:00:00 GMT CURAD Launches CURAD SoothePlus with ARM HAMMER Baking Soda for Enhanced Wound Care http://practicaldermatology.com/dermwire/view.asp?url=curad-launches-curad-sootheplus-with-arm--hammer-baking-soda-for-enhanced-wound-care CURAD® is rolling out CURAD SoothePlus™ Gauze and Pads which feature ARM & HAMMER™ baking soda for enhanced wound healing. Baking soda can soothe minor irritations, neutralize odor, relieve sting and provide relief. Soothe Plus complements CURAD’s portfolio of hospital-quality first aid products: Germ Shield, Soothe & Cool, QuickStop!, and Truly Ouchless! SoothePlus is now available at Meijer and will soon be offered at Kroger, Rite Aid, H-E-B and Publix st… Tue, 9 May 2017 04:00:00 GMT Valeant Appoints New Dermatology and Corporate Communications Leadership Members http://practicaldermatology.com/dermwire/view.asp?url=valeant-appoints-new-dermatology-and-corporate-communications-leadership-members Valeant Pharmaceuticals International, Inc. added new members to the dermatology leadership team -- Michael McMyne is the new Vice President of Sales and Stacey Williams is the new Vice President of Marketing. Additionally, the company appointed Lainie Keller as vice president of Corporate Communications. In his new role, Mr. McMyne will be responsible for the dermatology sales force. He most recently served as vice president of operations for Merz North America, Inc., where he launched a cha… Mon, 8 May 2017 04:00:00 GMT Fibrocell to Continue Phase 1/2 Clinical Trial of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa http://practicaldermatology.com/dermwire/view.asp?url=fibrocell-to-continue-phase-12-clinical-trial-of-fcx-007-for-recessive-dystrophic-epidermolysis-bullosa Fibrocell Science, Inc.’s Data Safety Monitoring Board (DSMB) has recommended continuation of the Phase 1/2 clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), following a review of safety data from the first patient treated. No product-related adverse events were reported. FCX-007 has been granted Orphan Drug, Rare Pediatric Disease and Fast Track Designations by the FDA. Fibrocell is developing FCX-007 in collaboration with Intrexon Corporati… Mon, 8 May 2017 04:00:00 GMT LEO Pharma U.S. Welcomes Judit H. Nyirady as Vice President of Medical Strategy Scientific Affairs http://practicaldermatology.com/dermwire/view.asp?url=leo-pharma-us-welcomes-judit-h-nyirady-as-vice-president-of-medical-strategy--scientific-affairs Judit H. Nyirady, MD, MBA, is the new Vice President of Medical Strategy & Scientific Affairs at LEO Pharma Inc. In this role, she will be responsible for the medical and scientific affairs strategies for LEO Pharma in the United States, as well as the U.S. Quality, Pharmacovigilance, Drug Safety, and Medical Information functions. Dr. Nyirady is a board certified dermatologist with more than 18 years of pharmaceutical experience in all aspects of clinical research and development. She a… Thu, 4 May 2017 04:00:00 GMT Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritis http://practicaldermatology.com/dermwire/view.asp?url=pfizer-announces-us-fda-filing-acceptance-of-supplemental-new-drug-application-for-xeljanz-tofacitinib-citrate-for-the-treatment-of-adult-patients-wit (via BusinessWire) Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) for the treatment of adult patients with active psoriatic arthritis (PsA). A separate sNDA was also accepted for XELJANZ XR® (tofacitinib citrate) extended release 11 mg once daily use in PsA. The sNDA submission is based on data from the Phase 3 Oral Psoriati… Thu, 4 May 2017 04:00:00 GMT La Roche-Posay Supports Oncodermatology Clinic at George Washington University http://practicaldermatology.com/dermwire/view.asp?url=la-roche-posay-supports-oncodermatology-clinic-at-george-washington-university La Roche-Posay, has partnered with the George Washington University Cancer Center to launch the GW Supportive Oncodermatology Clinic, with the first patients to be seen in mid-May at the GW Medical Faculty Associates. Under the leadership of Adam Friedman, MD, Associate Professor of Dermatology, Residency Program Director, and Director of Translational Research in the Department of Dermatology, the clinic will serve the comprehensive dermatologic needs of cancer patients by addressing the br… Thu, 4 May 2017 04:00:00 GMT Alastin to Present Study Results Demonstrating Anti-aging and Procedure Enhancement Results of TriHex Technology http://practicaldermatology.com/dermwire/view.asp?url=alastin-to-present-study-results-demonstrating-effectiveness-of-trihex-technology-for-post-laser-treatment-care Alastin Skincare, Inc. will present data on three new studies at the 7th Annual Summit in Aesthetic Medicine meeting in Newport Beach, CA (May 5-7, 2017). "As part of our commitment to generate scientific data related to our Alastin Skincare products and technology, we have been working closely with leading aesthetic physicians to generate clinical and non-clinical data supporting both our Procedure Enhancement line as well as our Restore & Renew daily skin care line. We are pleased … Thu, 4 May 2017 04:00:00 GMT